1997 1998 1999 2000 2001 2002 2003 2004
2005 2006 2007 2008
1. 2'-NH2-MPTP selectively lesions serotonin and norepinephrine nerve terminals in three species by a mechanism of action involving oxygen free radicals. National Institute on Drug Abuse Director’s Seminar Series, Baltimore, MD (June 15, 1997).
2. Attempts to unravel differential neurochemistry in serotonin transporter knock-out mice. National Institute of Mental Health, Bethesda, MD (November 18, 1998).
1999 top
3. Molecular mechanisms underlying adaptation of the presynaptic serotonin system in response to decreased SERT expression: Implications for understanding the etiology and treatment of depression and anxiety. Pennsylvania State University Neuroscience Day, Hershey Medical School, Hershey, PA (May 15, 1999).
2000 top
4. Tools to study the brain serotonin system: Neurotoxicological approaches. St. Vincent’s College, Department of Chemistry, Latrobe, PA (March 24, 2000).
5. The heterogeneous nature of the brain: Impact on etiology, diagnosis and treatment of anxiety disorders. SurroMed, Inc., Palo Alto, CA (May 8, 2000).
6. Criteria for evaluating neurotoxicity: Is 2'-NH2-MPTP a serotonergic neurotoxin? Pennsylvania State University Toxicology Forum, University Park, PA (May 10, 2000).
7. Tools to probe brain chemistry. Pennsylvania State University, Department of Bioengineering, University Park, PA (September 28, 2000).
8. The neurochemistry of anxiety. Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (November 3, 2000).
9. The neurochemistry of anxiety. Department of Chemistry, Bloomsburg University, Bloomsburg, PA (November 17, 2000).
10. Deciphering the neurochemistry of anxiety. Division of Neuropathology, Johns Hopkins Medical Institutions, Baltimore, MD (December 12, 2000).
2001 top
11. Deciphering the neurochemistry of anxiety. Central Nervous System Preclinical Research Division, Astra Zeneca, Wilmington, DE (February 15, 2001).
12. Deciphering the neurochemistry of anxiety. Department of Chemistry, Austin Peay University, Clarksville, TN (March 1, 2001).
13. Deciphering the neurochemistry of anxiety. Department of Chemistry, Western Kentucky University, Bowling Green, KY (March 2, 2001).
14. Deciphering the neurochemistry of anxiety. Department of Chemistry, Carlow College, Pittsburgh, PA (March 16, 2001).
15. Deciphering the neurochemistry of anxiety. College of Science Seminar Series, Grand Canyon University, Phoenix, AZ (March 23, 2001).
16. Deciphering the neurochemistry of anxiety. Department of Chemistry, Juniata College, Juniata, PA (September 12, 2001).
17. Using electrochemical techniques to analyze serotonin neurochemistry. Federation of Analytical Chemistry & Spectroscopy Societies, Detroit, MI (October 10, 2001).
2002 top
18. What can measuring serotonin in vivo tell us about anxiety? 2002 Pittsburgh Conference, New Orleans, LA (March 20, 2002).
19. Deciphering the neurochemistry of anxiety. Department of Chemistry, Olivet Nazarene University, Chicago, IL (April 1, 2002).
20. What do neuroscientists do? North Hills Junior High School, Pittsburgh, PA (May 3, 2002).
21. Measuring serotonin in the study of anxiety. NSF-REU Program, Department of Chemistry, James Madison University, Harrisonburg, VA (June 27, 2002).
22. The role of serotonin in MDMA-induced hyperactivity and neurotoxicity. Centers for Disease Control/National Institute for Occupational Safety and Health, Morgantown, WV (August 16, 2002).
23. Serotonin and the misbehaving brain. Department of Chemistry, Georgia Institute of Technology, Atlanta, GA (September 12, 2002).
24. Serotonin and the misbehaving brain. Department of Chemistry, Emory University, Atlanta, GA (September 13, 2002).
25. Serotonin and the misbehaving brain. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA (September 19, 2002).
26. Measurements in biological systems. Midwest Union of Analytical Chemistry Committee Meeting, University of Pittsburgh, Pittsburgh, PA (October, 3, 2002).
27. Serotonin and the misbehaving brain. Department of Chemistry, University of Texas at Austin, Austin, TX (October 17, 2002).
28. Is α-synuclein giving us the run around? Department of Neurology, Columbia University Medical School, New York, NY (October 24, 2002).
29. Electroanalytical methods elucidate modest but biologically relevant changes in serotonin and dopamine neurotransmission. Department of Chemistry, University of North Carolina, Chapel Hill, NC (November 11, 2002).
2003 top
30. Serotonin and its reciprocal relationship with BDNF. 35th Annual Winter Conference on Brain Research, Salt Lake City, UT (January 26, 2003).
31. Serotonin and the misbehaving brain. Department of Chemistry, Duke University, Raleigh-Durham, NC (February 7, 2003).
32. Electroanalytical methodology elucidates changes in serotonin and dopamine neurotransmission in genetically engineered mouse models of brain disease. 2003 Pittsburgh Conference, Orlando, FL (March 12, 2003).
33. Serotonin and the misbehaving brain. Department of Chemistry, St. Joseph’s University, Philadelphia, PA (April 2, 2003).
34. Serotonin and the fountain of youth: The chemistry of the aging brain. Department of Chemistry, Ohio State University, Columbus, OH (April 8, 2003).
35. SERT as a key regulator of serotonergic signaling and the effects on anxiety-related behavior. Monitoring Molecules in Neuroscience: 10th International Conference on In Vivo Methods, Stockholm, Sweden (June 25, 2003).
36. SERT as a key regulator of brain-derived neurotrophic factor expression. Monitoring Molecules in Neuroscience: 10th International Conference on In Vivo Methods, Stockholm, Sweden (June 25, 2003).
37. Novel tools for the dynamic analysis of brain chemistry. Midwest Union of Analytical Chemistry Committee Meeting, Indiana University Purdue University Indianapolis, Indianapolis, IN (October, 10, 2003).
38. Serotonin and the misbehaving brain: Using analytical chemistry to meet biologic challenges. Department of Chemistry, University of Illinois Urbana Champagne, Urbana, IL (October 24, 2003).
39. The relationship between serotonin and BDNF as trophic factors. 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (November 11, 2003).
2004 top
40. The effects of reduced serotonin transporter expression on neurotransmission, plasticity and behavior. National Center for Biological Sciences, TATA Institute, Bangalore, India (January 3, 2004).
41. Serotonin, reward and drugs of abuse. Department of Chemistry, University of Michigan, Ann Arbor, MI (February 19, 2004).
42. Serotonin and the misbehaving brain. Department of Chemistry, Muhlenberg College, Allentown, PA (May 4, 2004).
43. Serotonin degeneration and Alzheimer’s disease. Department of Chemistry, Trinity University, San Antonio, TX (September 30, 2004).
44. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. CrossOver 2004, Pennsylvania State University, University Park, PA (October 21, 2004).
45. Serotonin and the misbehaving brain. Chemistry Department Colloquium, The Pennsylvania State University, University Park, PA (November 4, 2004).
2005 top
46. Monoamine uptake revisited using carbon fiber microelectrodes and chronoamperometry. 37th Annual Winter Conference on Brain Research, Breckenridge, CO (January 22, 2005).
47. Serotonin in the aging brain: Can SRI’s be used to delay neurodegeneration? 2005 Analytical Grantee Symposium, Analytical Partnerships: Transforming Concepts into Medicines, Eli Lilly & Company, Indianapolis, IN (February 22, 2005).
48. Neurotransmitter chip for biosensor design and functionally-directed proteomics. Department of Chemistry, Tokyo Metropolitan University, Tokyo, Japan (March 22, 2005).
49. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Foundations of Nanoscience Meeting, Snowbird, UT (April 25, 2005).
50. Serotonin degeneration in Alzheimer’s disease. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA (May 24, 2005).
51. Serotonin and the misbehaving brain. Department of Biochemistry, Trinity College, Dublin, Ireland (December 9, 2005).
2006 top
52. The neurochip: nanostructured neurotransmitter derivatized surfaces for biosensor development. The Houston Society for Engineering in Medicine and Biology Annual Meeting, Houston, TX (February 10, 2006).
53. Serotonin uptake measured by chronoamperometry yields new insights into transporter function. National Institute of Mental Health, Bethesda, MD (February 22, 2006).
54. MDMA-induced serotonin and dopamine release does not stimulate locomotor activity in SERT knockout mice: Importance of 5-HT1B receptors. Monitoring Molecules in Neuroscience, 11th International Conference on In Vivo Methods, Sardinia, Italy (May 21, 2006).
55. Serotonin and the aging brain. Department of Neuroscience, Bordeaux 2 University, Bordeaux, France (July 25, 2006).
56. The neurochip: Nanostructured neurotransmitter derivatized surfaces for biosensor development. Department of Chemistry, University of California at Davis, Davis, CA (September 8, 2006).
57. Nanoscale study of heterogeneous brain architectures: Understanding disease mechanisms and devising novel therapeutics. 23rd National Meeting of the American Chemical Society Meeting, San Francisco, CA (September 10, 2006).
58. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Department of Chemistry, University of Wisconsin, Madison, WI (September 28, 2006).
59. The serotonin system as a potential therapeutic target in the treatment of early Alzheimer's disease. Department of Pharmacology, Penn State College of Medicine, Hershey, PA (October 9, 2006).
60. The unusual effects of MDMA and methamphetamine in mice with reduced serotonin transporter expression. Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX (November 15, 2006).
2007 top
61. Developing nanobiosensors for neurotransmitters: Assembly, patterning and application of optimally diluted biospecific capture surfaces. Mesilla Chemistry Workshop on Electron Transfer and Molecular Devices, Mesilla, NM (February 7, 2007).
62. Serotonin and the misbehaving brain: Unraveling the biology of anxiety and depression. Pennsylvania State University Lectures on the Frontiers of Science, University Park, PA (February 10, 2007).
63. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally directed proteomics. 58th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, Chicago, IL (February 28, 2007).
64. Genetic predisposition to a lifetime of anxiety: The serotonin transporter and brain-derived neurotrophic factor. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA (May 14, 2007).
65. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. Engineering Conferences International Conference on Nanoscience & Nanotechnology for Biological/Biomedical/Chemical Sensing, Hong Kong (June 6, 2007).
66. In search of brain nanobiosensors: Small molecule recognition as an important first step. 2007 International Conference on Scanning Probe Microscopies, Cantilever-Based Sensors, Nanostructures, Biosensors and Biochips, Jeju Island, South Korea (June 14, 2007).
67. Serotonin neurochemistry and the misbehaving brain. Hanyang University, Seoul, South Korea, June 18, 2007.
68. Genetic predisposition to a lifetime of anxiety: The serotonin transporter and brain-derived neurotrophic factor. School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX (October 8, 2007).
69. Influence of serotonin transporter gene variants on uptake and anxiety. Department of Chemistry, Vanderbilt University, Nashville, TN (October 30, 2007).
70. Why I became a scientist! Expanding Your Horizons Conference for 6th-8th grade girls, Women in Science and Engineering Program, Pennsylvania State University, University Park, PA (November 19, 2007).
71. Serotonin transporter: A genetic predisposition to a lifetime of anxiety. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA (November 26, 2007).
2008 top
72. Serotonin neurochemistry and the origins of anxiety. Department of Chemistry, Vanderbilt University, Nashville, TN (February 4, 2008).
73. In vivo approaches to investigating serotonin neurochemistry: From micro to nanoscales. American Chemical Society Susquehanna Valley Meeting, Lycoming College, Lycoming, PA (February 13, 2008).
74. Frightening complexity of the genetics of anxiety. Genetics Colloquium, Intercollege Program in Genetics, Pennsylvania State University, University Park, PA (February 15, 2008).
75. In search of brain nanobiosensors: Small molecule recognition as an important first step. 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 6, 2008).
76. New agonies over Ecstasy: Serotonin and psychostimulants. 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 6, 2008).
77. From genes to drugs: SERT-mediated regulation of BDNF, neurogenesis and anxiety. Serotonin Club Meeting, Oxford, England (July 17-19, 2008).
Contributed Presentations (presenter in bold)
1992 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003
2004 2005 2006 2007 2008
1992 top
1. 2'-Amino substituted MPTP depletes brain serotonin and norepinephrine without affecting dopamine in C57BL/6 mice. A. M. Andrews, N. A. Garrick and D. L. Murphy: 22nd Annual Meeting of the Society for Neuroscience, Anaheim, CA (1992).
1993 top
2. Uptake inhibitors selectively attenuate depletions in cortical and hippocampal serotonin and norepinephrine caused by 2'-NH2-MPTP in two strains of mice. A. M. Andrews and D. L. Murphy: 23rd Annual Meeting of the Society for Neuroscience, Washington, DC (1993).
3. 2'-NH2-MPTP in Swiss Webster mice: Evidence for long term depletions in cortical and hippocampal serotonin and norepinephrine and differential protection by selective uptake inhibitors or monoamine oxidase inhibitors. A. M. Andrews and D. L. Murphy: 1993 Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HA (1993).
1995 top
4. Acute neurotoxicity of 2'-NH2-MPTP: Changes in regional serotonin, 5-HIAA, norepinephrine, dopamine and GFAP levels in Swiss Webster mice. A. M. Andrews, D. B. Miller, J. P. O'Callaghan and D. L. Murphy: 25th Annual Meeting of the Society for Neuroscience, San Diego, CA (1995).
1996 top
5. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxicity of 2'-NH2-MPTP on serotonin and norepinephrine nerve terminals. A. M. Andrews, B. Ladenheim, J. L. Cadet and D. L. Murphy: 26th Annual Meeting of the Society for Neuroscience, Washington, DC (1996).
6. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A cross-species comparison versus MPTP and 2'-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996).
7. Targeted disruption of the murine serotonin transporter gene. D. Bengel, D. L. Murphy, A. M. Andrews, D. Feltner, C. H. Wichems, M. Seemann, A. Heils, A. Grinberg, H. Westphal and K.-P. Lesch: 1996 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR (1996).
1997 top
8. 2'-NH2-MPTP selectively depletes cortical and hippocampal 5-HT and NE in the rat: A comparison with 2'-CH3-MPTP. A. M. Andrews, P. Mazzola-Pomietto and D. L. Murphy: 1997 Joint Meeting of the International Society for Neurochemistry and the American Society for Neurochemistry, Boston, MA (1997).
9. The effects of MDMA on monoamine neurotransmitter levels and core temperature in mice with a disrupted serotonin transporter. A. M. Andrews, C. H. Wichems, D. Bengel, K.-P. Lesch and D. L. Murphy: 27th Annual Meeting of the Society for Neuroscience, New Orleans, LA (1997).
1998 top
10. A microdialysis study of the effects of high K+ and paroxetine on extracellular serotonin concentrations in serotonin transporter knock-out mice. A. M. Andrews, C. H. Wichems, Q. Li, A. Heils, K.-P. Lesch and D. L. Murphy: 28th Annual Meeting of the Society for Neuroscience, Los Angeles, CA (1998).
1999 top
11. A microdialysis study of the effects of genetic inactivation of the serotonin transporter gene on baseline and K+-stimulated extracellular serotonin concentrations in mouse striatum. D. E. Fedele and A. M. Andrews: Proceedings of the 8th International Conference on In Vivo Methods, Stony Brook, NY (1999).
12. The effects of PCPA on monoamine neurotransmitter levels in mice with a disruption of the serotonin transporter gene. D. L. Sheridan, C. H. Wichems, D. L. Murphy, and A. M. Andrews: 29th Annual Meeting of the Society for Neuroscience, Miami, FL (1999).
2000 top
13. Effects of serotonin transporter inactivation on extracellular 5-HT levels, in vivo microdialysis recovery, and MDMA-induced release of serotonin
and dopamine in mouse striatum. T. A. Mathews, D. E. Fedele, E. L. Unger, K.-P. Lesch, D. L. Murphy and A. M. Andrews: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000).
14. Binge-type behavior and brain serotonin. R. L. Corwin, S. F. Wagner, H. B. Rice and A. M. Andrews: 30th Annual Meeting of Society for Neuroscience, New Orleans, LA (2000).
15. Mechanisms mediating the increased anxiety-like and excess responses to stress in mice lacking the serotonin transporter. C. H. Wichems, Q. Li, A. Holmes, J. N. Crawley, O. Tjurmina, D. Goldstein, A. M. Andrews, K.-P. Lesch and D. L. Murphy: 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA (2000).
16. 5-HT reuptake in SERT knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).
17. BDNF regulation of serotonin functioning and plasticity. L. A. Mamounas, C. A. Altar, A. M. Andrews and W. E. Lyons: Serotonin Club/Brain Research Bulletin Conference, New Orleans, LA (2000).
2001 top
18. Quantitative microdialysis for serotonin in striatum and frontal cortex of genetically altered mice. D. E. Fedele, T. A. Mathews, L. A. Mamounas, W. E. Lyons and A. M. Andrews: Proceedings of the 9th International Conference on In Vivo Methods, Dublin, Ireland (2001).
19. Age-related changes in 5-HT immunocytochemistry in SERT knockout mice. A. M. Andrews, E. L. Unger, A. C. Chisnell, W. E. Lyons and L. A. Mamounas: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
20. Effects of 2'-NH2-MPTP in VMAT2 knockout mice. A. C. Chisnell, E. L. Unger, B. A. Fierst, D. L. Sheridan and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
21. Quantitative microdialysis for serotonin in BDNF knockout mice. T. A. Mathews, D. E. Fedele, L. A. Mamounas, W. E. Lyons and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
22. Dopamine uptake in serotonin transporter knockout mice by chronoamperometry. X. A. Perez and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
23. 5-HT, NE and BDNF levels in mice with pharmacologically or genetically-induced decreases in 5-HT uptake. M. E. Szapacs, C. M. McCann, E. L. Unger and A. M. Andrews: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
24. Cerebral amyloid deposition in APP/PS1 double transgenic mice is associated with induction of dystrophic serotonergic fibers. L. A. Mamounas, W. E. Lyons, O. Lee, W.-X. Li, W. Sterling, A. M. Andrews, E. L. Unger, A. C. Chisnell and M. K. Lee: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
25. Expression of human α-synuclein harboring the A53T, but not A30P, mutation leads to neurodegeneration in transgenic mice. M. K. Lee, W. Sterling, D. Eve, Y. Xu,, A. Mandir, T. Dawson V. Dawson A. M. Andrews and D. L. Price: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
26. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. I. Sora, F. S. Hall, A. M. Andrews, M. Itokawa, X.-F. Li, H.-B Wei, H. Yamamoto, T. Yamamoto, K. Ikeda, C. Wichems, K.-P. Lesch, D. L. Murphy and G. R. Uhl: 31st Annual Meeting of the Society for Neuroscience, San Diego, CA (2001).
2002 top
27. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk and A. M. Andrews: Gordon Research Conference on Bioanalytical Sensors, Ventura, CA (2002).
28. Adaptations in dopamine neurochemistry in SERT knockout mice by microdialysis and chronoamperometry. X. A. Perez, T. A. Mathews, A. C. Chisnell and A. M. Andrews: ACS 224th National Meeting, Boston, MA (2002).
29. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in forebrain. E. L. Unger, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002).
30. A53T α-synuclein transgenic mice show preclinical motor abnormalities that precede the development of fatal motoric dysfunction. E. L. Unger, D. K. Reichenbach, M. K. Lee and A. M. Andrews: World Alzheimer’s Congress, Stockholm, Sweden (2002).
31. Regionally selective and progressive degeneration of the 5-HT system in a transgenic mouse model of AD. M. J. Yoo, W. Stirling, O. Lee, W. X. Li, M. E. Blue, A. M. Andrews, W. E. Lyons, L. A. Mamounas and M. K. Lee: World Alzheimer’s Congress, Stockholm, Sweden (2002).
32. Electroanalytical methodology elucidates changes in synaptic 5-HT caused by intermediate reductions in SERT expression. A. M. Andrews, T. A. Mathews and X. A. Perez: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
33. RT-PCR analysis of BDNF mRNA in SERT knockout mice versus mice chronically treated with 5-HT reuptake inhibitors. K. J. Sowinski, M. E. Szapacs, C. M. McCann, E. L. Unger, D. J. Vandenbergh and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
34. Degeneration of serotonin axons is accompanied by decreased 5-HT and increased BDNF in a transgenic mouse model of AD. A. L. Numis, M. E. Szapacs, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
35. Preclinical motor abnormalities in A53T α-synuclein transgenic mice are age-dependent. D. K. Reichenbach, E. L. Unger, W. X. Li, D. Eve, M. K. Lee and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
36. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 32nd Annual Meeting of Society for Neuroscience, Orlando, FL (2002).
37. The effect of serotonin axon degeneration on functional 5-HT neurotransmission and behavior. M. D. Aponte, D. K. Reichenbach, B. A. Luellen, T. A. Mathews and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
38. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 32nd Annual Meeting of the Society for Neuroscience, Orlando, FL (2002).
2003 top
39. Decreased serotonin transporter expression prevents age-related serotonergic fiber loss in the forebrain. E. L. Unger, B. A. Luellen, O. Lee, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 35th Annual Winter Conference on Brain Research, Salt Lake City, UT (2003).
40. Electroanalytical methods elucidate the role of mutant α-synuclein in dopamine neurotransmission and Parkinson’s disease. X. A. Perez, T. A. Mathews, E. L. Unger, D. K. Reichenbach, M. K. Lee and A. M. Andrews: 2003 Pittsburgh Conference, Orlando, FL (2003).
41. Synthesis of serotonin or dopamine coupled to solid support permitting interaction of all available functional groups. M. E. Szapacs, E. D. Horowitz, R. S. Bridges, P. C. Bevilacqua, R. L. Funk and A. M. Andrews: 2003 Pittsburgh Conference, Orlando, FL (2003).
42. Serotonin and the fountain of youth: An examination of age-related serotonergic axon preservation versus serotonin levels in the forebrain of serotonin transporter knockout mice. A. L. Numis, E. L. Unger, B. A. Luellen, and A. M. Andrews: 2003 Undergraduate Exhibition, Pennsylvania State University, University Park, PA (2003).
43. Basal extracellular and METH-induced striatal DA levels in SERT knockout mice. T. A. Mathews, E. L. Unger, A. C. Chisnell and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
44. BDNF levels in SERT knockout mice and their responsiveness to stress. M. E. Szapacs, A. P. McGraw, K. J. Sowinski and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
45. Role of the vesicular monoamine transporter in the neurotoxic effects of 2'-NH2-MPTP in mice and rats. A. L. Numis and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
46. Serotonin may be necessary for the astrocytic response to neuronal injury: Studies using 2'-NH2-MPTP. B. A. Luellen, A. L. Numis, D. L. Murphy, D. B. Miller, J. P. O’Callaghan and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
47. Quantitative microdialysis in BDNF knockout mice. L. A. Killingbeck, T. A. Mathews, W. E. Lyons, L. A. Mamounas and A. M. Andrews: 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA (2003).
2004 top
48. Chronoamperometric determination of serotonin transporter function in synaptosomes: Comparison with traditional radiochemical methods. X. A. Perez, C. M. Squillante and A. M. Andrews: 2004 Pittsburgh Conference, Chicago, IL (2004).
49. The role of mitogen activated protein kinase pathways in age-related neuroprotection in serotonin transporter knockout mice. J. E. Cavanaugh, T. Smith, E. L. Unger, B. A. Luellen, A. M. Andrews and J. M. Lakoski: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).
50. The role of increased extracellular serotonin in age-related changes in serotonergic and catecholaminergic forebrain innervation and astrocytic response. B. A. Luellen, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: Serotonin Satellite Symposium of the 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).
51. Constitutive reductions in SERT expression alter age-dependent changes in serotonin innervation patterns. B. A. Luellen, E. L. Unger, W. E. Lyons, M. E. Blue, L. A. Mamounas and A. M. Andrews: 4th Meeting of the Federation of European Pharmacological Societies, Porto, Portugal (2004).
52. Late onset loss of hippocampal 5-HT and NE is accompanied by an increase in BDNF protein expression in mice co-expressing mutant APP and PS1. M. E. Szapacs, A. L. Numis and A. M. Andrews: The 9th International Conference of Alzheimer’s Disease and Related Disorders, Philadelphia, PA (2004).
53. 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine increase BDNF levels and compromise the structural integrity of neurons. B. A. Luellen, M. E. Szapacs, A. P. McGraw, A. L. Numis and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 24, 2004).
54. Serotonin transporter knockout mice exhibit gene dose-dependant variations in extracellular serotonin and extraction fraction in hippocampus. L. E. Killingbeck and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 24, 2004).
55. Chronoamperometric determination of serotonin transporter function in synaptosomes: Comparison with traditional radiochemical methods. X. A. Perez and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 25, 2004).
56. Differential effects of MDMA and METH on motor activity and striatal 5-HT and DA release in SERT knockout mice. A. M. Andrews, E. L. Unger and T. A. Mathews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 26, 2004).
57. BDNF mRNA and protein levels in SERT knockout mice as a function of age and cellular and environmental stress factors. A. P. McGraw, M. E. Szapacs, D. J. Vandenbergh and A. M. Andrews: 34th Annual Meeting of the Society for Neuroscience, San Diego, CA (October 26, 2004).
2005 top
58. The neurochip: An advanced nanomaterial for the development of novel biosensors and functionally-directed proteomics. A. M. Andrews: ChinaNANO 2005, Bejing, China (June 9, 2005).
59. Chronoamperometry versus radiochemical methods for determining serotonin uptake: Why such discrepancies? X. A. Perez, L. E. Killingbeck,
A. M. Andrews: New Perspectives in Neurotransmitter Transporter Biology, 15th Neuropharmacology Conference, Washington, DC (November 9, 2005).
60. MDMA-induced dopamine release does not stimulate locomotor activity in SERT knockout mice: Role of extracellular serotonin and the 5-HT1B receptor. T. A. Mathews, E. L.Unger, D. E. Fedele, K.-P. Lesch, D. L. Murphy, A. M. Andrews: New Perspectives in Neurotransmitter Transporter Biology, 15th Neuropharmacology Conference, Washington, DC (November 10, 2005).
61. Methods to evaluate serotonin neurotransmission and BDNF in aging and degenerative and psychiatric diseases. A. M. Andrews: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 14, 2005).
62. Reduced BDNF expression is associated with potentiated loss of serotonergic innervation in the hippocampus of aging mice. B. A. Luellen, L. E. Killingbeck, L. M. Schneider and A. M. Andrews: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 13, 2005).
63. Altered serotonin synthesis, turnover, and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. D.-T. Kim, T. J. Tolliver, S. Huang, B. J. Martin, A. M. Andrews, A. Holmes, K.-P Lesch and D. L. Murphy: 35th Annual Meeting of the Society for Neuroscience, Washington, DC (November 13, 2005).
64. Serotonin transport measured using carbon fiber microelectrodes and chronoamperometry yields new insights into brain function. A. M. Andrews and X. A. Perez: PacifiChem 2005, Honolulu, HI (December 17, 2005).
65. Nanostructured neurotransmitter-derivatized surfaces for biosensor development. A. M. Andrews, M. E. Szapacs, A. S. Cans, A. U. Vaish, J. L. Han, M. E. Anderson and P. S. Weiss: PacifiChem 2005, Honolulu, HI (December 19, 2005).
2006 top
66. Nanostructured neurotransmitter-derivatized surfaces for biosensor development. A. U. Vaish, M. J. Shuster, M. V. Pishko, P. S. Weiss and A. M. Andrews: Gordon Conference on Biosensors, Ventura, CA (February 28, 2006).
67. The neurochip: An advanced nanomaterial for small molecule capture of biomolecule binding partners. A. U. Vaish, M. J. Shuster, P. S. Weiss, M. V. Pishko and A. M. Andrews: Materials Research Society, Spring 2006 Meeting, San Francisco, CA (April 18, 2006).
68. Single molecule placement of small molecule probes in SAMs allows selective recognition by large biomolecule binding partners. A. M. Andrews, A. U. Vaish, M. J. Shuster and P. S. Weiss: Foundations of Nanoscience (FNANO 06) Self-Assembled Architectures and Devices, Snowbird, UT (April 25, 2006).
69. The neurotoxin 2'-NH2-MPTP models degeneration of serotonin axons and alterations in hippocampal BDNF occurring in Alzheimer's disease. A. M. Andrews, C. K. Materese, M. E. Szapacs and B. A. Luellen: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain (July 18, 2006).
70. A physical model of axonal damage due to oxidative stress. P. S. Weiss, A. E. Counterman, T. G. D’Onofrio and A. M. Andrews: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid, Spain (July 18, 2006).
71. The neurochip: An advanced nanosurface for small molecule capture of biomolecule binding partners. M. J. Shuster, A. U. Vaish, T. J. Mullen, P. S. Weiss and A. M. Andrews: CrossOver 2006, University Park, PA (October 12, 2006).
72. Single molecule placement of serotonin in self-assembled monolayers allows selective recognition by antibodies and native transmembrane receptors. P. S. Weiss, M. J. Shuster, A. U. Vaish and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 14, 2006).
73. Mice lacking the serotonin transporter maintain robust increases in anxiety-related behavior and show reduced hippocampal neurogenesis into old age. S. Pajtek, B. A. Luellen and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 17, 2006).
74. High-speed chronoamperometric determination of serotonin transporter function in human lymphoblasts. Y. Singh, A. J. Bressler, R. Ren-Patterson, D. L. Murphy and A. M. Andrews: 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA (October 17, 2006).
2007 top
75. Behavioral inhibition in a novel physical environment is unrelated to social investigation. N. Vasudevan, C. E. Kovacsics, S. A. Cavigelli, A. J. Bressler, A. M. Andrews and B. C. Jones: 11th Annual Society of Behavioral Endocrinology Meeting, Pacific Grove, CA (June 22, 2007).
76. Hippocampal cellular proliferation is decreased in aging SERT null mutant mice. M. K. Zhao and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007).
77. Serotonin uptake rates in synaptosomes using boron-doped diamond electrodes. Y. S. Singh, B. A. Patel, A. J. Bressler, G. M. Swain and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007).
78. Serotonin release and reuptake using in vivo fast cyclic voltammetry in serotonin transporter deficient mice. Y. S. Singh, B. A. Patel, A. J. Bressler, G. M. Swain and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007).
79. Aging mice with reduced BDNF expression show improved learning and memory in a low stress route learning task. A. J. Bressler, T. N. Chrzanowski, A. R. Lewis, L. Tessarrollo, D. A. Blizard and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007).
80. Recombinant inbred mouse strains as tools to identify new genes underlying anxiety. A. R. Lewis, A. J. Bressler, B. C. Jones, S. A. Cavagelli, N. Vasudevan and A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 7, 2007).
81. Marble burying in aging serotonin transporter (SERT) deficient mice. C. A. Lieu, A. J. Bressler, A. R. Lewis, R. J. Milner, A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007).
82. Anxiety-related behavior, locomotor activity and route learning in aging APP/PS1 transgenic mice. M. M. Maxon, T. N. Chrzanowski, A. J. Bressler, A. R. Lewis, D. A. Blizard, A. M. Andrews: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3, 2007).
83. Deficits in gamma2 subunit containing GABA-A receptors affect neuronal maturation independently of changes in BDNF and serotonergic transmission. N. Sahir, B. A. Luellen, J. C. Earnheart, A. M. Andrews and B. Lüscher: 37th Annual Meeting of the Society for Neuroscience, San Diego, CA (November 3-7, 2007).
2008 top
84. Using high-speed chronoamperometry to determine native serotonin transporter function in human lymphoblasts. A. J. Bressler, T. N. Chrzanowski, R. Ren-Patterson, D. L. Murphy and A. M. Andrews: 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 3, 2008).
85. Small molecule functionalized capture materials for functionally-directed brain proteomics and neurotransmitter sensing. A. Vaish, M. J. Shuster, P. S. Weiss and A. M. Andrews: 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, LA (March 1-7, 2008).
back
